Abstract
This review focuses primarily on the mammalian medium and long-chain fatty acid coenzyme A ligases that have been implicated in the metabolism of xenobiotic carboxylic acids such as pesticides, arylpropionate non steroidal anti-inflammatory drugs and the hypolipidaemic clofibrate and its congeners. Evidence of multiplicity of mitochondrial and microsomal enzymes and their respective substrate/inhibitor profiles are discussed. For completeness, where appropriate, details of non-substrate inhibitors have also been included. Although knowledge is limited at present with respect to the medium-chain enzymes, aspects of regulation particularly the in vivo, in vitro role of peroxisome proliferators and current knowledge of the molecular biology of the long-chain fatty acid CoA ligase superfamily are documented. Additionally, alignment of thirteen cloned mammalian fatty acid CoA ligases using criteria established for the CYP and UGT superfamilies has enabled construction of a phylogenetic tree that clearly defines three families. Catalytic data are still limited and the xenobiotic substrate/inhibitor profiles of the recombinant proteins are incomplete. Finally, with increasing recognition of the importance of fatty acyl-CoA esters as physiological regulators of cell function including gene expression, the review concludes with a discussion of the metabolic fate and toxicity of xenobiotic acyl-CoA esters.
Current Drug Metabolism
Title: Xenobiotic-CoA Ligases: Kinetic and Molecular Characterization
Volume: 1 Issue: 1
Author(s): K. M. Knights and C. J. Drogemuller
Affiliation:
Abstract: This review focuses primarily on the mammalian medium and long-chain fatty acid coenzyme A ligases that have been implicated in the metabolism of xenobiotic carboxylic acids such as pesticides, arylpropionate non steroidal anti-inflammatory drugs and the hypolipidaemic clofibrate and its congeners. Evidence of multiplicity of mitochondrial and microsomal enzymes and their respective substrate/inhibitor profiles are discussed. For completeness, where appropriate, details of non-substrate inhibitors have also been included. Although knowledge is limited at present with respect to the medium-chain enzymes, aspects of regulation particularly the in vivo, in vitro role of peroxisome proliferators and current knowledge of the molecular biology of the long-chain fatty acid CoA ligase superfamily are documented. Additionally, alignment of thirteen cloned mammalian fatty acid CoA ligases using criteria established for the CYP and UGT superfamilies has enabled construction of a phylogenetic tree that clearly defines three families. Catalytic data are still limited and the xenobiotic substrate/inhibitor profiles of the recombinant proteins are incomplete. Finally, with increasing recognition of the importance of fatty acyl-CoA esters as physiological regulators of cell function including gene expression, the review concludes with a discussion of the metabolic fate and toxicity of xenobiotic acyl-CoA esters.
Export Options
About this article
Cite this article as:
Knights M. K. and Drogemuller J. C., Xenobiotic-CoA Ligases: Kinetic and Molecular Characterization, Current Drug Metabolism 2000; 1 (1) . https://dx.doi.org/10.2174/1389200003339261
DOI https://dx.doi.org/10.2174/1389200003339261 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Current Pharmaceutical Design Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Management of Measurable Variable Cardiovascular Disease' Risk Factors
Current Cardiology Reviews Therapeutical Perspectives of S-Allylcysteine: Effect on diabetes and other disorders in Animal Models
Cardiovascular & Hematological Agents in Medicinal Chemistry Developments in Non-Surgical Therapies for Abdominal Aortic Aneurysm
Current Vascular Pharmacology The Antidiabetic Therapeutic Potential of Dietary Polyphenols
Current Pharmaceutical Biotechnology Subject Index To Volume 4
Current Vascular Pharmacology Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period
Current Clinical Pharmacology A Refined Framework for Precision and Translational Proteomics in Clinical Research
Current Proteomics Understanding the Molecular and Cellular Changes Behind Aortic Valve Stenosis
Current Pharmaceutical Biotechnology Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Effect of Glyoxal Modification on a Critical Arginine Residue (Arg-31α) of Hemoglobin: Physiological Implications of Advanced Glycated end Product an <i>in vitro</i> Study
Protein & Peptide Letters An Insight to the Toxic Effect of Sulfamerazine on Porcine Pancreatic Amylase and Lactate Dehydrogenase Activity: An In Vitro Study
Current Chemical Biology Cholinesterase Inhibitors Slow Decline in Executive Functions, Rather than Memory, in Alzheimers Disease: A 1-Year Observational Study in the Sunnybrook Dementia Cohort
Current Alzheimer Research Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety 3,4,5-Trihydroxybenzoic Acid Attenuates Ligature-Induced Periodontal Disease in Wistar Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Association of Selected Adipocytokines and Inflammatory Markers on Body Mass Index in Type 2 Diabetes Patients in Saudi Arabia and as Risk Factors to Cardiovascular Disease
Current Diabetes Reviews GLUT4 Associated Proteins as Therapeutic Targets for Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Astrocytic 5-HT2B Receptor as in vitro and in vivo Target of SSRIs
Recent Patents on CNS Drug Discovery (Discontinued) Insulin Resistance and the Renin-Angiotensin-Aldosterone System in Metabolic Syndrome and Obesity-Related Hypertension
Current Hypertension Reviews